---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-052213"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:28:53.994772+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BiomX exits phage therapy, pivots to defense/security via DFSL and Zorronet acquisitions

## Summary
- Discontinued all clinical trials; former BiomX Ltd. subsidiary filed for insolvency in Israel in Dec 2025.
- Acquired 60% of DFSL (LADAR detection) and 100% of Zorronet (AI security platform) to enter defense markets.
- New management: Michael Oster as CEO, David Rokach as CFO appointed in Q1 2026.
- Established X Security & Defense subsidiary; committed over $3M for 2026 operations.
- Zorronet has projects with Elbit Systems (NIS 500k) and Rafael; DFSL LADAR ~99% detection accuracy.

## SEC filing metadata
- accession: 0001213900-26-052213
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390026052213/0001213900-26-052213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390026052213/ea0289209-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-052213
- JSON: https://secwatch.observer/filing/0001213900-26-052213.json
- Plain text: https://secwatch.observer/filing/0001213900-26-052213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.